Linsitinib is a potent and selective dual inhibitor of insulin-like growth factor 1 (IGF-1R) kinase and insulin receptor (InsR) kinase (IC50s = 35 and 75 nM respectively).1 It has been investigated as a chemotherapeutic in combination with other drugs f
* VAT and and shipping costs not included. Errors and price changes excepted